Despite the competitive nature for funding in the crowded weight loss treatment space, Metsera has won $215m to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) orientated portfolio.

Shares of obesity drug developers were volatile this week amid good news for Eli Lilly's (LLY) drug candidate orforglipron, bad news for Pfizer's (PFE) danuglipron and uncertainty about whether ...

Obesity drug developers Structure Therapeutics (NASDAQ:GPCR) and Metsera (NASDAQ ... its data in terms of a secondary endpoint linked to weight loss caught the attention of Wall Street.

Pfizer to discontinue danuglipron weight-loss drug, but has other obesity treatments ... "second-most advanced" oral GLP-1 in development. Metsera Inc. also stands to benefit, as while its oral ...

Viking Therapeutics (NASDAQ:VKTX) and other developers of oral weight loss drugs traded sharply higher on Tuesday after ...

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is ...

Second, in GLP-1s, we continue to advance our partnership with Metsera in the weight loss and obesity space, which represents a new integrated business model to drive innovation at scale in GLP-1s.

Shares of Viking Therapeutics, Altimmune, Structure Therapeutics and Metsera — all of which have weight loss drugs in clinical testing — rose in trading Monday.

A1c and weight loss were at least as good as semaglutide ... Merck Sharp & Dohme, Metsera, Novartis, Novo Nordisk, Pfizer, Sanofi, and Roche and received grant support paid to his university ...